<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825604</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr: 056-08</org_study_id>
    <nct_id>NCT00825604</nct_id>
  </id_info>
  <brief_title>Quality of Life and Target Achievement After Treatment of Patients With Stable Angina Pectoris</brief_title>
  <acronym>LOBSTR</acronym>
  <official_title>Quality of Life and Achievement of Target of Treatment After Optimized Medical Treatment, Physical Training and Smoking Cessation With or Without Percutaneous Coronary Intervention in Patients With Stable Angina Pectoris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to, in patients with stable angina pectoris, assess the
      additional benefit of PCI on top of optimized medical treatment, physical training and
      smoking cessation with regard to quality of life, achievement of target of treatment and
      clinical events such as death, acute myocardial infarction, stroke and revascularization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with stable angina pectoris with a significant coronary stenosis will be randomized
      to optimized medical treatment, physical training and smoking cessation or to optimized
      medical treatment, physical training, smoking cessation and complimentary treatment with PCI.
      All patients will be followed up at six months and at one and five years regarding symptoms,
      blood lipids, systemic blood pressure, physical training status, smoking habits, and maximal
      exercise ECG.

      Achievement of target of treatment will be measured by questions regarding the patients'
      expectation of the treatment at baseline and at a 6 month follow-up. The questions at 6
      months will be based on the interviews at inclusion. Furthermore quality of life will be
      measured with three different measuring instrument; SF-36 short form, Seattle Angina
      Questionnaire (SAQ), and EQ-5D. These instruments will be given to the patients at baseline,
      at six months and at the five year follow up.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Because of poor inclusion difficulties to find patient
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life measured by SF36</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of target of treatment based on interview of the patients</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, myocardial infarction, stroke or new revascularization</measure>
    <time_frame>6 months, one year and five years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess expectations of treatment at inclusion and fulfilment of expectations</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by EQ5D and Seattle angina questionaire</measure>
    <time_frame>6 months and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economy</measure>
    <time_frame>6 months, one year and five years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Stable Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Without PCI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Optimized medical treatment, physical training and smoking cessation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>optimized medical treatment, physical training and smoking cessation with complimentary treatment with percutaneous coronary intervention(PCI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary angioplasty (PCI)</intervention_name>
    <description>optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):</description>
    <arm_group_label>With PCI</arm_group_label>
    <other_name>PCI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable coronary artery disease

          -  Angina pectoris with at least angina class 2 according to Canadian Cardiovascular
             Society (CCS)

          -  Angiographic verified stenos in a native vessel

          -  Accepted for PCI

        Exclusion Criteria:

          -  Instable coronary artery disease or AMI withín two months

          -  CCS class IV

          -  Stenosis in Left main and/or proximal LAD

          -  NYHA- III-IV

          -  Fall in blood pressure during exercise test &gt; 10mm Hg, measured two times

          -  Contraindication or allergy against clopidogrel or ASA

          -  Unable to communicate verbal or i writing

          -  Unwillingness to participate in the study

          -  Participating in an other study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Grip, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborgs Universty</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. Epub 2007 Mar 26.</citation>
    <PMID>17387127</PMID>
  </reference>
  <reference>
    <citation>Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, Chamberlain DA; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003 Oct 1;42(7):1161-70.</citation>
    <PMID>14522473</PMID>
  </reference>
  <reference>
    <citation>Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999 Jul 8;341(2):70-6.</citation>
    <PMID>10395630</PMID>
  </reference>
  <reference>
    <citation>Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE; COURAGE Trial Research Group, Mancini GB. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008 Aug 14;359(7):677-87. doi: 10.1056/NEJMoa072771.</citation>
    <PMID>18703470</PMID>
  </reference>
  <reference>
    <citation>Sullivan M, Karlsson J. The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population. J Clin Epidemiol. 1998 Nov;51(11):1105-13.</citation>
    <PMID>9817128</PMID>
  </reference>
  <reference>
    <citation>Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol. 1994 Dec 15;74(12):1240-4.</citation>
    <PMID>7977097</PMID>
  </reference>
  <reference>
    <citation>Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995 Feb;25(2):333-41.</citation>
    <PMID>7829785</PMID>
  </reference>
  <reference>
    <citation>Sullivan M, Karlsson J, Ware JE Jr. The Swedish SF-36 Health Survey--I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med. 1995 Nov;41(10):1349-58.</citation>
    <PMID>8560302</PMID>
  </reference>
  <reference>
    <citation>Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996 Jul 6;313(7048):36-9. Erratum in: BMJ 1996 Aug 31;313(7056):550.</citation>
    <PMID>8664772</PMID>
  </reference>
  <reference>
    <citation>Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001 Jul;33(5):337-43. Review.</citation>
    <PMID>11491192</PMID>
  </reference>
  <reference>
    <citation>Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, Erbs S, Kluge R, Kendziorra K, Sabri O, Sick P, Schuler G. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004 Mar 23;109(11):1371-8. Epub 2004 Mar 8.</citation>
    <PMID>15007010</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <last_update_submitted>March 16, 2012</last_update_submitted>
  <last_update_submitted_qc>March 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <name_title>Lars Grip M D PhD Prof</name_title>
    <organization>Sahlgrenska University Hospital, Sweden</organization>
  </responsible_party>
  <keyword>stable coronary artery disease</keyword>
  <keyword>quality of life</keyword>
  <keyword>target achievement</keyword>
  <keyword>physical training</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

